Pacira cut to Hold after Viatris agrees $36.50-a-share deal; stock jumps 44%

Needham downgraded Pacira BioSciences to Hold after Viatris agreed to buy the company for $36.50 per share in cash, valuing it at about $1.65 billion, according to Financial Modeling Prep. Shares spiked and options activity turned sharply bearish.